|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Formation and operational costs | ||||
| Revenues | ||||
| Subscription fees | ||||
| Professional services and other fees | ||||
| Technical engineering fees | ||||
| Patient fees | ||||
| Telehealth fees | ||||
| Institutional fees | ||||
| Total revenues | ||||
| Cost of revenues | ||||
| Gross margin | ||||
| Compensation and related benefits | ||||
| Goodwill impairment charges | ||||
| General and administrative | ||||
| Transaction expenses | ||||
| Total operating expenses | ||||
| Net operating loss | ||||
| Other (expense) income | ||||
| Initial fair value of Additional Bridge Note | ||||
| Initial fair value of ELOC | ||||
| Change in fair value | ||||
| Additional Bridge Promissory note | ||||
| Exchange Note | ||||
| Change in fair value of ELOC | ||||
| Change in fair value of Bifurcated Derivative | ||||
| Bridge Notes | ||||
| Extension Notes | ||||
| Change in fair value of PIPE Forward Contract Derivative | ||||
| Interest earned on investments held in Trust Account | ||||
| Interest expense | ||||
| Bridge Notes | ||||
| Additional Bridge Promissory note | ||||
| Promissory note - M2B | ||||
| Extension Notes | ||||
| Total interest expense | ||||
| Other income, net | ||||
| Change in fair value of financial instruments | ||||
| Gain on extinguishment of Equity Line of Credit (“ELOC”) | ||||
| Change in fair value on embedded derivative | ||||
| Gain on forgiveness of debt | ||||
| Loss on issuance of financial instruments | ||||
| Total other (expense) income, net | ||||
| Loss before (provision for) benefit from income taxes | ||||
| (Provision for) benefit from income taxes | ||||
| Net loss | ||||
| Net profit attributable to non-controlling interest | ||||
| Net loss attributable to stockholders | ||||
| Basic loss per common share (in Dollars per share) | ||||
| Diluted loss per common share (in Dollars per share) | ||||
| Weighted average number of common shares outstanding, basic (in Shares) | ||||
| Weighted average number of common shares outstanding, diluted (in Shares) | ||||
Loading...